Compare BridgeBio Pharma Inc (BBIO) vs Zillow Group Inc Class A (ZG) Price & Performance

BridgeBio Pharma (BBIO) trades at $84.67, up 0.22% today, with a bullish technical signal and strong analyst consensus. Despite missing Q2 2026 EPS estimates with a loss of $0.78 per share, revenue beat expectations as Attruby sales surged 311% year-over-year. The company maintains a high gross margin of 94.44% but reports negative net income and cash flow from operations, reflecting its growth investment phase.

The outlook is optimistic due to multiple late-stage pipeline catalysts, including three potential product launches by mid-2027 and an FDA decision on encaleret by May 2027. Risks include sustained cash burn, high debt of $1.72 billion, and clinical trial execution. The consensus price target of $104.56 implies significant upside if commercial execution succeeds.

Zillow Group (ZG) trades at $34.07, up 0.35% with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with 2025 revenue of $2.58B and a return to profitability ($23M net income) after years of losses. However, valuation remains elevated with a P/E of 149, while multiple class action lawsuits create near-term uncertainty. The stock faces resistance at $35 with support at $33.

ZG presents a mixed investment case with strong revenue growth and business model transition offset by legal overhangs and high valuation. The preferred agent model drives monetization improvement, but the stock requires careful risk management given the legal proceedings and technical bearish signals. Upside exists to the $47.56 consensus target if execution continues.